MX390949B - Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. - Google Patents
Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.Info
- Publication number
- MX390949B MX390949B MX2018000598A MX2018000598A MX390949B MX 390949 B MX390949 B MX 390949B MX 2018000598 A MX2018000598 A MX 2018000598A MX 2018000598 A MX2018000598 A MX 2018000598A MX 390949 B MX390949 B MX 390949B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- antibody fragments
- cancer treatment
- radiolabeled antibody
- emitter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193700P | 2015-07-17 | 2015-07-17 | |
| EP16153372 | 2016-01-29 | ||
| PCT/EP2016/066934 WO2017013026A1 (en) | 2015-07-17 | 2016-07-15 | Radiolabelled antibody fragments for use in treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000598A MX2018000598A (es) | 2018-05-11 |
| MX390949B true MX390949B (es) | 2025-03-21 |
Family
ID=57833837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000598A MX390949B (es) | 2015-07-17 | 2016-07-15 | Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11298433B2 (enExample) |
| EP (1) | EP3325020B1 (enExample) |
| JP (1) | JP6917357B2 (enExample) |
| KR (1) | KR20180042226A (enExample) |
| CN (1) | CN108025093B (enExample) |
| AU (1) | AU2016294858B2 (enExample) |
| CA (1) | CA2991398A1 (enExample) |
| MX (1) | MX390949B (enExample) |
| WO (1) | WO2017013026A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11517632B2 (en) * | 2017-06-20 | 2022-12-06 | Nanomab Technology Limited | Anti-Her2 single chain antibody and coding sequence and use thereof |
| EP3967674A1 (en) * | 2020-09-11 | 2022-03-16 | Precirix N.V. | Reactions of radioactive compounds facilitated by a solid phase |
| CN112561871B (zh) * | 2020-12-08 | 2021-09-03 | 中国医学科学院北京协和医院 | 一种基于平扫ct图像的主动脉夹层分割方法和装置 |
| CN117321081A (zh) * | 2021-02-22 | 2023-12-29 | 雅博得乐医疗公司 | 用于靶向放射性同位素疗法的免疫缀合物 |
| EP4529540A1 (en) * | 2022-05-23 | 2025-04-02 | Cereius, Inc. | Her2-binding agents and uses thereof |
| EP4577578A1 (en) | 2022-08-22 | 2025-07-02 | Abdera Therapeutics Inc. | Dll3 binding molecules and uses thereof |
| CN116719074A (zh) * | 2023-05-29 | 2023-09-08 | 中国核电工程有限公司 | 一种两栖生物辐射剂量率的获取方法及装置 |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| AU707159B2 (en) | 1994-09-16 | 1999-07-01 | Cancer Research Fund Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
| WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
| WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
| CA2370351A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| AU1859201A (en) | 1999-11-29 | 2001-06-12 | Unilever Plc | Immobilisation of proteins |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| ATE428733T1 (de) | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| EP1360207B1 (en) | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| US20090304590A1 (en) | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| CN101970490A (zh) * | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| EP2807189B1 (en) | 2012-01-23 | 2019-03-20 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| CA2906259C (en) | 2013-03-15 | 2022-12-06 | Vib Vzw | Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases |
| US10174117B2 (en) * | 2013-06-11 | 2019-01-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| WO2016016329A1 (en) | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
| CN106573983B (zh) | 2014-07-29 | 2018-05-25 | 布鲁塞尔自由大学 | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 |
-
2016
- 2016-07-15 MX MX2018000598A patent/MX390949B/es unknown
- 2016-07-15 JP JP2018502118A patent/JP6917357B2/ja active Active
- 2016-07-15 CN CN201680053382.1A patent/CN108025093B/zh active Active
- 2016-07-15 EP EP16745643.3A patent/EP3325020B1/en active Active
- 2016-07-15 US US15/742,161 patent/US11298433B2/en active Active
- 2016-07-15 CA CA2991398A patent/CA2991398A1/en active Pending
- 2016-07-15 WO PCT/EP2016/066934 patent/WO2017013026A1/en not_active Ceased
- 2016-07-15 AU AU2016294858A patent/AU2016294858B2/en active Active
- 2016-07-15 KR KR1020187001952A patent/KR20180042226A/ko not_active Ceased
-
2022
- 2022-03-11 US US17/692,315 patent/US12440586B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3325020A1 (en) | 2018-05-30 |
| WO2017013026A1 (en) | 2017-01-26 |
| EP3325020B1 (en) | 2022-01-12 |
| MX2018000598A (es) | 2018-05-11 |
| US11298433B2 (en) | 2022-04-12 |
| CN108025093A (zh) | 2018-05-11 |
| JP6917357B2 (ja) | 2021-08-11 |
| CA2991398A1 (en) | 2017-01-26 |
| CN108025093B (zh) | 2022-02-11 |
| AU2016294858B2 (en) | 2022-08-11 |
| AU2016294858A1 (en) | 2018-02-01 |
| BR112018000672A2 (pt) | 2018-09-18 |
| KR20180042226A (ko) | 2018-04-25 |
| US12440586B2 (en) | 2025-10-14 |
| US20220323620A1 (en) | 2022-10-13 |
| JP2018532689A (ja) | 2018-11-08 |
| US20180200393A1 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390949B (es) | Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer. | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
| CL2021000353A1 (es) | Anticuerpo o fragmento de anticuerpo del mismo que comprende una región de unión que se une a un supresor del dominio vista, composición que lo comprende, su uso para tratar o prevenir el cáncer, ácido nucleico aislado, vector de expresión, célula hospedadora, método para producir dicho anticuerpo o fragmento del mismo, y artículo de fabricación (divisional de solicitud n° 01646-2016) | |
| MX2024015844A (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| ECSP19086810A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2017013613A (es) | Neoepitodos de cancer. | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| WO2016062722A8 (en) | Combination | |
| EA201990183A1 (ru) | Аденовирус, вооруженный биспецифичным активатором т-клеток (bite) | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| MX388015B (es) | Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer. | |
| EA201790834A1 (ru) | Молекулы антител к pd-l1 и их применение | |
| MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| AR113429A1 (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moléculas biespecíficas de linfocitos t | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| HUE057901T2 (hu) | Összetételek és módszerek rák kezelésére argininkiürítéssel és immunonkológiai szerekkel | |
| BR112018013094A2 (pt) | combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano | |
| MX2024004299A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos. |